These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 21835486)

  • 1. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
    Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
    Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF; Van Acker KL; De Leeuw IH
    Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
    Gerstein HC; Garon J; Joyce C; Rolfe A; Walter CM
    Diabet Med; 2004 Nov; 21(11):1200-3. PubMed ID: 15498086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of incretins in oral glucose and lipid tolerance tests may be indicative in the diagnosis of metabolic syndrome aggravation.
    Kiec-Klimczak M; Malczewska-Malec M; Razny U; Zdzienicka A; Gruca A; Goralska J; Pach D; Gilis-Januszewska A; Dembinska-Kiec A; Hubalewska-Dydejczyk A
    J Physiol Pharmacol; 2016 Apr; 67(2):217-26. PubMed ID: 27226181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
    Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
    Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin clearance and incretin hormones following oral and "isoglycemic" intravenous glucose in type 2 diabetes patients under different antidiabetic treatments.
    Tura A; Göbl C; Vardarli I; Pacini G; Nauck M
    Sci Rep; 2022 Feb; 12(1):2510. PubMed ID: 35169165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
    Manzella D; Grella R; Abbatecola AM; Paolisso G
    Diabetes Care; 2005 Feb; 28(2):366-71. PubMed ID: 15677794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
    Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
    Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial plasma incretin hormones in exercise-trained versus untrained subjects.
    Weiss EP; Royer NK; Fisher JS; Holloszy JO; Fontana L
    Med Sci Sports Exerc; 2014 Jun; 46(6):1098-103. PubMed ID: 24576859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
    Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
    Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
    Højberg PV; Vilsbøll T; Rabøl R; Knop FK; Bache M; Krarup T; Holst JJ; Madsbad S
    Diabetologia; 2009 Feb; 52(2):199-207. PubMed ID: 19037628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.